Zealand Pharma A/S
ZEAL
Classificação em ações
#5519
Zealand Pharma A/S is a Danish biotechnology firm dedicated to the... Zealand Pharma A/S is a Danish biotechnology firm dedicated to the identification, progression, and market introduction of peptide-based therapeutics. The company concentrates its efforts on treatments for gastrointestinal and metabolic ailments, as well as other specialized conditions where current medical options are insufficient. Its commercialized product, Dasiglucagon, is an injectable solution provided in a pre-filled syringe or autoinjector, used to address severe hypoglycemia. Furthermore, Zealand Pharma is actively developing Dasiglucagon for inclusion in bi-hormone artificial pancreas systems that integrate both insulin and dasiglucagon. The compound Dasiglucagon is also undergoing late-stage (Phase III) clinical trials for congenital hyperinsulinism. Another significant asset in its development pipeline is glepaglutide, a long-acting GLP-2 analog, which is likewise in Phase III clinical studies for treating short bowel syndrome. Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S maintains strategic alliances with a range of partners, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.
Preço da ação
$35.20
Valor de mercado
$2.44B
Variação (1 dia)
-1.77%
Variação (1 ano)
-50.84%
País
DK
Negociar Zealand Pharma A/S (ZEAL)
Categoria
Healthcare
Capitalização de mercado de Zealand Pharma A/S(ZEAL)
Valor de mercado: $2.44B
Em October 2026, Zealand Pharma A/S tem uma capitalização de mercado de $2.44B. Isso faz com que Zealand Pharma A/S seja a 5519th empresa mais valiosa do mundo em termos de capitalização de mercado, de acordo com os nossos dados. A capitalização de mercado, também chamada de market cap, é o valor total de mercado das ações em circulação de uma empresa de capital aberto e é amplamente utilizada para medir o valor de uma empresa.
Histórico de capitalização de mercado de Zealand Pharma A/S de 2013 a 2026
ZEAL comparado com o topo de 5 mais populares stocks
